MUMBAI, India, June 6 -- Intellectual Property India has published a patent application (202517048248 A) filed by Boehringer Ingelheim International Gmbh, Ingelheim am Rhein, Germany, on May 19, for 'heterocyclic compounds as sting antagonists.'
Inventor(s) include Hoffmann, Matthias; Brambilla, Marta; Dahmann, Georg; Gross, Patrick; Handschuh, Sandra Ruth; Li, Jun; Mayer, Camilla; Nar, Herbert; and Oost, Thorsten.
The application for the patent was published on June 6, under issue no. 23/2025.
According to the abstract released by the Intellectual Property India: "This invention relates to compounds of formula (1), and their use as STING antagonists e.g. for the treatment of a disease selected from the group consisting of systemic lupus erythematosus (SLE), (monogenic and digenic) interferonopathies (including STING-associated vasculopathy with onset in infancy (SAVI), Aicardi-Goutieres syndrome (AGS), COPA syndrome, and familial chilblain lupus), type 1 interferonopathies with mutations in DNASE2 or ATAD3A genes, age-related macular degeneration (AMD), retinopathy, glaucoma, amyotrophic lateral sclerosis (ALS), diabetes, obesity, inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), Bloom's syndrome, Sjogren's syndrome, Parkinson's disease, heart failure and cancer, systemic sclerosis (SSc), dermatomyositis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatotic hepatitis (NASH), acute on chronic liver failure (ACLF), interstitial lung disease (ILD), idiopathic pulmonary fibrosis (IPF), aging/muscle disorders, sepsis, heart failure, rheumatoid arthritis and osteoarthritis."
The patent application was internationally filed on Oct. 26, 2023, under International application No.PCT/EP2023/079890.
Disclaimer: Curated by HT Syndication.
